Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Steven P. Treon, M.D., Ph.D.

Co-Author

Back to Details
This page shows the publications co-authored by Steven Treon and Andrew Branagan.
Steven Treon
Connection Strength
4.224
Andrew Branagan
  1. Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. Blood Adv. 2022 02 08; 6(3):1015-1024.
    View in: PubMed
    Score: 0.246
  2. Venetoclax in Previously Treated Waldenström Macroglobulinemia. J Clin Oncol. 2022 01 01; 40(1):63-71.
    View in: PubMed
    Score: 0.243
  3. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. Blood. 2021 10 28; 138(17):1535-1539.
    View in: PubMed
    Score: 0.242
  4. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022 02; 36(2):532-539.
    View in: PubMed
    Score: 0.240
  5. Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia. Br J Haematol. 2021 08; 194(4):730-733.
    View in: PubMed
    Score: 0.231
  6. Clinical application of genomics in Waldenström macroglobulinemia. Leuk Lymphoma. 2021 08; 62(8):1805-1815.
    View in: PubMed
    Score: 0.230
  7. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2021 02 20; 39(6):565-575.
    View in: PubMed
    Score: 0.224
  8. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020 04 10; 38(11):1198-1208.
    View in: PubMed
    Score: 0.215
  9. Genomic landscape of Waldenström's macroglobulinemia. Hemasphere. 2019 Jun; 3(Suppl).
    View in: PubMed
    Score: 0.206
  10. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2009 Jan 01; 15(1):355-60.
    View in: PubMed
    Score: 0.099
  11. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood. 2009 Apr 16; 113(16):3673-8.
    View in: PubMed
    Score: 0.099
  12. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4452-7.
    View in: PubMed
    Score: 0.097
  13. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4683-9.
    View in: PubMed
    Score: 0.093
  14. Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol. 2007 Sep; 35(9):1366-75.
    View in: PubMed
    Score: 0.091
  15. Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2007 Aug; 7 Suppl 5:S199-206.
    View in: PubMed
    Score: 0.090
  16. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007 Jun 01; 13(11):3320-5.
    View in: PubMed
    Score: 0.089
  17. Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol. 2007 Jan; 82(1):83-4.
    View in: PubMed
    Score: 0.086
  18. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma. 2007 Jan; 7(4):286-90.
    View in: PubMed
    Score: 0.086
  19. Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia. Arch Ophthalmol. 2006 Nov; 124(11):1601-6.
    View in: PubMed
    Score: 0.085
  20. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol. 2006 Aug; 17(8):1275-82.
    View in: PubMed
    Score: 0.083
  21. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma. 2006 May; 6(6):478-83.
    View in: PubMed
    Score: 0.083
  22. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood. 2006 May 01; 107(9):3442-6.
    View in: PubMed
    Score: 0.081
  23. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol. 2006 Mar; 17(3):488-94.
    View in: PubMed
    Score: 0.080
  24. CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005 Mar; 5(4):246-9.
    View in: PubMed
    Score: 0.076
  25. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol. 2005 Jan 20; 23(3):474-81.
    View in: PubMed
    Score: 0.076
  26. Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol. 2005 Jan; 16(1):132-8.
    View in: PubMed
    Score: 0.075
  27. Clinical responses to sildenafil in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2004 Dec; 5(3):205-7.
    View in: PubMed
    Score: 0.075
  28. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol. 2004 Oct; 15(10):1481-3.
    View in: PubMed
    Score: 0.074
  29. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):121-6.
    View in: PubMed
    Score: 0.067
  30. A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Adv. 2022 Mar 07.
    View in: PubMed
    Score: 0.062
  31. Targeted Therapies and Emerging Novel Treatment Approaches for Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2022 Feb 24.
    View in: PubMed
    Score: 0.062
  32. Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia. Hemasphere. 2021 Aug; 5(8):e624.
    View in: PubMed
    Score: 0.059
  33. Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica. 2021 Jun 24.
    View in: PubMed
    Score: 0.059
  34. Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenström macroglobulinemia. Am J Hematol. 2021 07 01; 96(7):E250-E253.
    View in: PubMed
    Score: 0.058
  35. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020 Nov; 7(11):e827-e837.
    View in: PubMed
    Score: 0.056
  36. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. Hemasphere. 2020 Aug; 4(4):e433.
    View in: PubMed
    Score: 0.055
  37. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):127-31.
    View in: PubMed
    Score: 0.017
  38. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):110-5.
    View in: PubMed
    Score: 0.017
  39. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):116-20.
    View in: PubMed
    Score: 0.017
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.